ClinicalTrials.gg
CompletedNCT06435624Updated Mar 5, 2025Results posted

Effectiveness of Intelligent Rehabilitation Robot Training System Combined With Repetitive Facilitative Exercise on Upper Limb Motor Function After Stroke: a Randomized Control Trial.

An interventional study of intelligent robotic-assisted training and repetitive facilitative exercise in Stroke, sponsored by Nanjing Mingzhou Rehabilitation Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Nanjing Mingzhou Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Enrollment
292nd of 432
81 · median 169
Started
2024
with 70 others
No phase
264 of 613
123 open now
Registered
416th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 292nd largest by enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 264 with no phase, and was the 416th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if intelligent rehabilitation robot training system combined with repetitive facilitative exercise (RFE) work to treat stroke in adults. The main questions it aims to answer are:

Does drug intelligent rehabilitation robot training system combined with RFE improve the upper limb motor function of participants? Can the combination of intelligent rehabilitation robot training system and RFE achieve better effects?

Researchers will compare 3 groups (RFE, intelligent rehabilitation robot training system under RFE, and conventional therapy) to see if intelligent rehabilitation robot training system and RFE works to treat stroke.

Participants will:

Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients (18 to 74 years old) who suffered a first or second unilateral stroke
  • chronic stroke (over 6 months from the onset)
  • obvious upper limb movement disorders (FMA-UE scores from 25 to 42)
  • ability to understand and follow simple directions

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating
  • upper extremity contracture, pain, or trauma
  • perceptual, apraxic, or cognitive deficits that lead to inability to follow verbal instructions
  • unable to maintain sitting posture
  • cerebellar lesion
  • clinically unstable medical disorders
  • inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    IRAT group

    The Intelligent robotic-assisted training (IRAT) group received a 30 minute RFE intervention and a 30 minute IRAT intervention.

    Device: intelligent robotic-assisted training · Other: repetitive facilitative exercise

  • Active comparator
    RFE group

    The Repetitive facilitative exercise (RFE) group received a 60 minute RFE intervention.

    Other: repetitive facilitative exercise

  • Active comparator
    CT group

    The Conventional therapy (CT) group received a 60 minute conventional rehabilitation intervention.

    Other: conventional therapy

Interventions

  • Deviceintelligent robotic-assisted training

    Using an intelligent robotic-assisted training (IRAT) system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function. The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd.

  • Otherrepetitive facilitative exercise

    Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.

  • Otherconventional therapy

    Basic training, including passive joint movement and activities of daily living exercise.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment for Upper Extremity (FMA-UE)

    The FMA-UE consists of 33 items across nine components, including reflex action, synergy, and coordination, with a maximum score of 66 points. Each items is scored from 0 (no ability) to 2 (full ability), with higher scores indicating better upper limb motor function.

    Time frame: From enrollment to the end of treatment at 4 weeks

  2. Active Participation Proportion

    Active Participation Proportion (APP) is measured using the benchmark evaluation system within the intelligent rehabilitation robot training system. The robotic arm's mechanical sensor continuously detects the force exerted by the patient during the test game and quantifies APP as the ratio of the patient's applied force to the total force required to complete the task (%). A higher APP indicates greater voluntary effort in movement execution. Since the test game difficulty is fixed, APP increases as the patient's motor ability improves.

    Time frame: From enrollment to the end of treatment at 4 weeks

  3. Trajectory Deviation

    Trajectory Deviation (TD) is assessed by comparing the actual motion trajectory with a predefined reference trajectory using the intelligent rehabilitation robot training system. TD is calculated as the mean Euclidean distance (in mm) between discrete points along the actual movement path and the nearest corresponding points on the reference trajectory. This metric provides a measure of point-specific accuracy and precision in following the ideal movement path, with smaller TD values indicating better trajectory control.

    Time frame: From enrollment to the end of treatment at 4 weeks

  4. Trajectory Tracking Error

    Description: Trajectory Tracking Error (TTE) quantifies the cumulative deviation between the actual movement path and the predefined reference trajectory. It is computed as the sum of absolute differences in trajectory length between the two paths (in mm). TTE reflects overall movement efficiency and smoothness, capturing the patient's ability to maintain an optimal movement path throughout the task. A lower TTE indicates better movement planning and motor control.

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Results

Posted Mar 5, 2025
Limitations and caveats
The intervention period was relatively short and lacked long-term follow-up.

Participant flow

Participant flow — Overall Study
MilestoneIRAT GroupRFE GroupCT Group
Started272727
Completed252625
Not completed212

Outcome measures

PrimaryFugl-Meyer Assessment for Upper Extremity (FMA-UE)

The FMA-UE consists of 33 items across nine components, including reflex action, synergy, and coordination, with a maximum score of 66 points. Each items is scored from 0 (no ability) to 2 (full ability), with higher scores indicating better upper limb motor function.

Time frame:
From enrollment to the end of treatment at 4 weeks
Reported as:
Mean · score on a scale
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
score on a scaleIRAT GroupRFE GroupCT Group
baseline34.4 ± 3.534.9 ± 3.835.8 ± 3.9
4 weeks49.0 ± 3.344.2 ± 3.638.8 ± 3.8
PrimaryActive Participation Proportion

Active Participation Proportion (APP) is measured using the benchmark evaluation system within the intelligent rehabilitation robot training system. The robotic arm's mechanical sensor continuously detects the force exerted by the patient during the test game and quantifies APP as the ratio of the patient's applied force to the total force required to complete the task (%). A higher APP indicates greater voluntary effort in movement execution. Since the test game difficulty is fixed, APP increases as the patient's motor ability improves.

Time frame:
From enrollment to the end of treatment at 4 weeks
Reported as:
Mean · percentage of active participation
Active Participation Proportion
percentage of active participationIRAT GroupRFE GroupCT Group
baseline61.7 ± 4.8104.0 ± 7.960.8 ± 6.1
4 weeks80.4 ± 5.361.6 ± 2.860.9 ± 2.6
PrimaryTrajectory Deviation

Trajectory Deviation (TD) is assessed by comparing the actual motion trajectory with a predefined reference trajectory using the intelligent rehabilitation robot training system. TD is calculated as the mean Euclidean distance (in mm) between discrete points along the actual movement path and the nearest corresponding points on the reference trajectory. This metric provides a measure of point-specific accuracy and precision in following the ideal movement path, with smaller TD values indicating better trajectory control.

Time frame:
From enrollment to the end of treatment at 4 weeks
Reported as:
Mean · millimeter
Trajectory Deviation
millimeterIRAT GroupRFE GroupCT Group
baseline104.0 ± 7.9100.7 ± 8.999.5 ± 8.3
4 weeks65.7 ± 8.098.1 ± 5.795.7 ± 4.7
PrimaryTrajectory Tracking Error

Description: Trajectory Tracking Error (TTE) quantifies the cumulative deviation between the actual movement path and the predefined reference trajectory. It is computed as the sum of absolute differences in trajectory length between the two paths (in mm). TTE reflects overall movement efficiency and smoothness, capturing the patient's ability to maintain an optimal movement path throughout the task. A lower TTE indicates better movement planning and motor control.

Time frame:
From enrollment to the end of treatment at 4 weeks
Reported as:
Mean · millimeter
Trajectory Tracking Error
millimeterIRAT GroupRFE GroupCT Group
baseline60.8 ± 6.160.5 ± 6.061.6 ± 5.8
4 weeks36.8 ± 6.658.0 ± 2.859.1 ± 2.8

Adverse events

Collected over All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IRAT Group———
RFE Group———
CT Group———

Baseline characteristics

Age, Continuous
Age, Continuous(years)IRAT GroupRFE GroupCT GroupTotal
Mean51.6 ± 12.346.8 ± 11.750.3 ± 14.049.5 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)IRAT GroupRFE GroupCT GroupTotal
Female1010929
Male15161647
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IRAT GroupRFE GroupCT GroupTotal
American Indian or Alaska Native0000
Asian25262576
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)IRAT GroupRFE GroupCT GroupTotal
China25262576
Affected side, left/right
Affected side, left/right(participants)IRAT GroupRFE GroupCT GroupTotal
left12121438
right13141138
Time from stroke, days
Time from stroke, days(days)IRAT GroupRFE GroupCT GroupTotal
Mean256.2 ± 60.1254.7 ± 46.0270.1 ± 55.8260.3 ± 53.9
08

Study locations

1 site
  • Nanjing Mingzhou Rehabilitation Hospital
    Nanjing, Jiangsu 210046, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Aug 2024, 2 months.

Results were first posted in Mar 2025, 6 months after primary completion.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 2 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 30, 2024
StartActual
Jun 15, 2024
Primary completionActual
Aug 31, 2024
CompletionActual
Aug 31, 2024
Results first posted
Mar 5, 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06435624
Lead sponsor
Nanjing Mingzhou Rehabilitation Hospital
Responsible party
Jingzhi Zhang (technician, Nanjing Mingzhou Rehabilitation Hospital) — Principal investigator
First posted
May 30, 2024
Start date
Jun 15, 2024
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Results posted
Mar 5, 2025
Last update
Mar 5, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion